(Press-News.org)
New York and Cambridge, UK -- Recent research demonstrates that protein phase separation (PPS) is widely present in cells and drives a variety of important biological functions. Protein phase separation at the wrong place or time could create clogs or aggregates of molecules linked to neurodegenerative diseases like Alzheimer’s and Parkinson’s, and poorly formed cellular condensates could contribute to cancers and might help explain the aging process.
Given the emerging association between human disease and the PPS process, scientists have been looking for ways to identify potential targets for therapeutic interventions based on PPS regulation. Today, Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and University of Cambridge jointly published a paper in Proceedings of the National Academy of Sciences (PNAS), presenting an approach to identify therapeutic targets for human diseases associated with PPS. It represents a significant research milestone in their collaboration, launched in September 2021.
In this study, researchers combined Insilico's proprietary artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method for predicting protein separation to identify PPS-prone disease-associated proteins. PandaOmics integrates multiple omics and text-based AI bioinformatics models to assess the potential of proteins as therapeutic targets. The FuzDrop is a pioneering tool introduced by Prof. Michele Vendruscolo’s group at the University of Cambridge, which calculates the propensity of a protein to undergo spontaneous phase separation, aiding in the identification of proteins prone to forming liquid-liquid phase-separated condensates.
“It has been challenging so far to understand the role of protein phase separation in cellular functions,” said Prof. Michele Vendruscolo, Co-Director, Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, and lead author on the paper. "Even more difficult has been to clarify the exact nature of its association with human disease. By working with Insilico Medicine, we have developed a multi-omic approach to systematically address this problem and identify a variety of possible targets for therapeutic intervention. We have thus provided a roadmap for researchers to navigate this complex terrain.”
Using this approach, the researchers conducted a large-scale multi-omic study of human sample data, quantified the relative impact of PPS in regulating various pathological processes associated with human disease, prioritized candidates with high PandaOmics and FuzDrop scores, and generated a list of possible therapeutic targets for human diseases linked with PPS.
Researchers validated the differential phase separation behaviors of three predicted Alzheimer’s disease targets (MARCKS, CAMKK2 and p62) in two cell models of Alzheimer’s disease, which provides experimental validation for the involvement of these predicted targets in Alzheimer's disease and supports their potential as therapeutic targets. By modulating the formation and behavior of these condensates, it may be possible to develop novel interventions to mitigate the pathological processes associated with Alzheimer's disease.
“We are pleased to reach this milestone in our collaboration with the University of Cambridge,” said Frank Pun, PhD, head of Insilico Medicine Hong Kong, and co-author of the paper. “The study is intended to provide initial directions for targeting PPS-prone disease-associated proteins. With ongoing technical advancements in studying the PPS process, coupled with growing data about its roles in both cellular function and dysfunction, it is now possible to comprehend the causal relationship between PPS targets and diseases. We anticipate facilitating the translation of this preclinical research into novel therapeutic interventions in the near future.”
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS), and aging-related diseases. For more information, visit www.insilico.com
END
Scientists have found a surprising effect of some antibiotics on certain bacteria – that the drugs can sometimes benefit bacteria, helping them live longer.
Until now, it has been widely acknowledged that antibiotics kill bacteria or stop them growing, making them widely used as blanket medication for bacterial infections. In recent years, the rise of antibiotic resistance has stopped some antibiotics from working, meaning that untreatable infections could be the biggest global cause of death by 2050.
Now, researchers at the University of Exeter have shown for the first time that antibiotics ...
A team led by researchers at Johns Hopkins Bloomberg School of Public Health and the National Cancer Institute has developed a new algorithm for genetic risk-scoring for major diseases across diverse ancestry populations that holds promise for reducing health care disparities.
Genetic risk-scoring algorithms are considered a promising method to identify high-risk groups of individuals who could benefit from preventive interventions for various diseases and conditions, such as cancers and heart diseases. ...
A new Dartmouth study in the journal Science Advances suggests that how well people with diabetes manage their blood sugar depends on their experience with the condition and their overall success in controlling their glucose levels, as well as on the season and time of day. The findings could help physicians identify those patients who could benefit from more guidance in regulating their blood sugar, particularly at certain times of year.
The researchers accessed data from wearable glucose monitors that showed how 137 people in the U.S. aged 2 to 76 living primarily with type 1, aka juvenile, diabetes managed their blood sugar on a daily basis. By analyzing more ...
As a physical quantity pressure is encountered in various fields: atmospheric pressure in meteorology, blood pressure in medicine, or even in everyday life with pressure cookers and vacuum-sealed foods. Pressure is defined as a force per unit area acting perpendicular to a surface of a solid, liquid, or gas. Depending on the direction in which the force acts within a closed system, very high pressure can lead to explosive reactions in extrem cases, while very low pressure in a closed system can cause the implosion of the system itself. Overpressure ...
A digital twin may sound like something out of a science fiction film, but Pitt engineers are developing new technology to make them a reality in our campus and beyond.
Digital twins – a model that serves as a real-time computational counterpart – can be used to help simulate the effects of multiple types of conditions, such as weather, traffic, and even climate change. Still, life-cycle assessments (LCAs) of climate change’s effects on infrastructure are still a work-in-progress, leaving a need ...
In the future, quantum computers may be able to solve problems that are far too complex for today’s most powerful supercomputers. To realize this promise, quantum versions of error correction codes must be able to account for computational errors faster than they occur.
However, today’s quantum computers are not yet robust enough to realize such error correction at commercially relevant scales.
On the way to overcoming this roadblock, MIT researchers demonstrated a novel superconducting qubit ...
A new injectable solution that self-assembles into a gel under the right conditions could help manage HIV unlike any currently available methods, researchers have found.
The gel releases a steady dose of the anti-HIV drug lamivudine over six weeks, suggesting people living with HIV could have new therapy that doesn’t require a daily pill regimen to prevent AIDS.
“The primary challenge in HIV treatment is the need for lifelong management of the virus, and one way to address this is to reduce dosing frequencies to help patients stick to medical regimens,” said Honggang Cui, a Johns Hopkins University chemical and biomolecular engineer ...
Study finds immune cells in older adults resemble those in newborns and children, but fall short in virus detection
A world-first discovery has revealed special immune cells called ‘killer T cells’ in older adults, directed against influenza viruses, closely resemble those found in newborns and children, but struggle to recognise infected cells – a finding that unlocks the potential for the development of better vaccines and therapies tailored to different age groups.
Killer T cells (also known as CD8+ T cells) play a critical role in the immune system by eliminating virus-infected cells. ...
Wang Studying Novel & Interpretable Statistical Learning For Brain Imaging Data
Lily Wang, Professor, Statistics, has received a total grant of $1,199,772 ($299,987 for the first year) from the National Institutes of Health for the project: "SCH: Novel and Interpretable Statistical Learning for Brain Images in AD/ADRDs." This funding began in Sept. 2023 and will end in late April 2027. This grant was reviewed by the joint NSF/NIH Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) program.
Alzheimer’s ...
PLYMOUTH MEETING, PA [September 25, 2023] —Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader at a national reception in Chicago in June. This achievement comes as the NCCN Chemotherapy Order Templates (NCCN Templates®) program celebrates its 15th anniversary and launches new resources for a type of pediatric lymphoma today.
40 Under 40 in Cancer is an awards initiative that recognizes ...
